161 related articles for article (PubMed ID: 22064354)
1. Oral high-dose glucocorticoids and ofatumumab in fludarabine-resistant chronic lymphocytic leukemia.
Spaner DE
Leukemia; 2012 May; 26(5):1144-5. PubMed ID: 22064354
[No Abstract] [Full Text] [Related]
2. High-dose glucocorticoids plus Ofatumumab in fludarabine/alemtuzumab-resistant B-cell chronic lymphocytic leukemia.
Vannata B; Innocenti I; Autore F; Sorà F; Chiusolo P; Leone G; Sica S; Laurenti L
Am J Hematol; 2012 Dec; 87(12):E133. PubMed ID: 23115113
[No Abstract] [Full Text] [Related]
3. Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study.
Österborg A; Jewell RC; Padmanabhan-Iyer S; Kipps TJ; Mayer J; Stilgenbauer S; Williams CD; Hellmann A; Furman RR; Robak T; Hillmen P; Trnêný M; Dyer MJ; Piotrowska M; Kozak T; Gupta IV; Phillips JL; Goldstein N; Struemper H; Losic N; Lisby S; Wierda WG;
Haematologica; 2015 Aug; 100(8):e311-4. PubMed ID: 25769539
[No Abstract] [Full Text] [Related]
4. What choices are available for treatment of the patient with chronic lymphocytic leukemia who is fludarabine-refractory?
Byrd JC; Rai KR
Semin Oncol; 2000 Aug; 27(4):xii-xv; discussion xv-xvi. PubMed ID: 10950363
[No Abstract] [Full Text] [Related]
5. U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.
Lemery SJ; Zhang J; Rothmann MD; Yang J; Earp J; Zhao H; McDougal A; Pilaro A; Chiang R; Gootenberg JE; Keegan P; Pazdur R
Clin Cancer Res; 2010 Sep; 16(17):4331-8. PubMed ID: 20601446
[TBL] [Abstract][Full Text] [Related]
6. Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.
Ferrajoli A; Wierda WG; LaPushin R; O'Brien SM; Faderl S; Browning ML; Keating MJ
Eur J Haematol; 2008 Apr; 80(4):296-8. PubMed ID: 18182081
[TBL] [Abstract][Full Text] [Related]
7. Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia.
Reagan JL; Castillo JJ
Expert Rev Anticancer Ther; 2011 Feb; 11(2):151-60. PubMed ID: 21342032
[TBL] [Abstract][Full Text] [Related]
8. An open-label, single-arm, phase 1 study to assess biomarker effects, efficacy and safety of ofatumumab in patients with refractory chronic lymphocytic leukemia.
Patton WN; Lindeman R; Butler AC; Kipps TJ; Jewell RC; Laubscher KH; Zhou YY; Lewis E; Sedoti D; Witman P; Fang L; Chan G
Leuk Lymphoma; 2015; 56(10):2819-25. PubMed ID: 25721750
[TBL] [Abstract][Full Text] [Related]
9. 2-Chlorodeoxyadenosine (2-CdA) in chronic lymphocytic leukemia refractory to fludarabine?
Schirmer M; Michlmayr G; Geisen F; Konwalinka G
Leukemia; 1996 Jul; 10(7):1253-4. PubMed ID: 8684013
[No Abstract] [Full Text] [Related]
10. Fludarabine plus rituximab for untreated B-cell chronic lymphocytic leukemia.
Castagna L; Sarina B; Santoro A
Blood; 2003 Sep; 102(6):2309; author reply 2309-10. PubMed ID: 12959942
[No Abstract] [Full Text] [Related]
11. Repeated rituximab maintenance courses in fludarabine-failed young patients with chronic lymphocytic leukaemia responding to FAND chemotherapy.
Scaramucci L; Niscola P; Buffolino S; Bongarzoni V; Cimino G; Montanaro M
Hematol J; 2004; 5(2):186-7. PubMed ID: 15048071
[No Abstract] [Full Text] [Related]
12. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.
Wierda WG; Kipps TJ; Mayer J; Stilgenbauer S; Williams CD; Hellmann A; Robak T; Furman RR; Hillmen P; Trneny M; Dyer MJ; Padmanabhan S; Piotrowska M; Kozak T; Chan G; Davis R; Losic N; Wilms J; Russell CA; Osterborg A;
J Clin Oncol; 2010 Apr; 28(10):1749-55. PubMed ID: 20194866
[TBL] [Abstract][Full Text] [Related]
13. [Successful treatment for advanced and refractory chronic lymphocytic leukemia with fludarabine phosphate].
Takeuchi M; Tada A; Soda R; Takahashi K
Rinsho Ketsueki; 1997 Sep; 38(9):792-4. PubMed ID: 9364873
[TBL] [Abstract][Full Text] [Related]
14. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
Rai KR; Peterson BL; Appelbaum FR; Kolitz J; Elias L; Shepherd L; Hines J; Threatte GA; Larson RA; Cheson BD; Schiffer CA
N Engl J Med; 2000 Dec; 343(24):1750-7. PubMed ID: 11114313
[TBL] [Abstract][Full Text] [Related]
15. High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy.
Dungarwalla M; Evans SO; Riley U; Catovsky D; Dearden CE; Matutes E
Haematologica; 2008 Mar; 93(3):475-6. PubMed ID: 18310545
[TBL] [Abstract][Full Text] [Related]
16. Oral fludarabine: a viewpoint by David Oscier.
Oscier D
Drugs; 2003; 63(21):2324-5. PubMed ID: 14524735
[No Abstract] [Full Text] [Related]
17. High-dose methylprednisolone can induce remissions in patients with fludarabine-refractory chronic lymphocytic leukaemia.
Xu W; Miao KR; Hong M; Zhu DX; Fang C; Dong HJ; Wang DM; Cao X; Li JY
Eur J Cancer; 2010 Aug; 46(12):2145-9. PubMed ID: 20627536
[TBL] [Abstract][Full Text] [Related]
18. A comparison of the efficacy and safety of oral and intravenous fludarabine in chronic lymphocytic leukemia in the LRF CLL4 trial.
Dearden CE; Richards S; Else M; Catovsky D; Hillmen P
Cancer; 2011 Jun; 117(11):2452-60. PubMed ID: 24048793
[TBL] [Abstract][Full Text] [Related]
19. 2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine.
Saven A; Lemon RH; Piro LD
N Engl J Med; 1993 Mar; 328(11):812-3. PubMed ID: 8094889
[No Abstract] [Full Text] [Related]
20. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.
Stilgenbauer S; Zenz T; Winkler D; Bühler A; Schlenk RF; Groner S; Busch R; Hensel M; Dührsen U; Finke J; Dreger P; Jäger U; Lengfelder E; Hohloch K; Söling U; Schlag R; Kneba M; Hallek M; Döhner H;
J Clin Oncol; 2009 Aug; 27(24):3994-4001. PubMed ID: 19597025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
